Incannex Completes Successful Pre-IND Meeting with the FDA f

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse. The pre-IND teleconference included representatives f

Related Keywords

United States , Melbourne , Victoria , Australia , Laine Yonker , Joel Latham , Drug Administration , Edison Group , Incannex Healthcare Inc , Nasdaq , Investigational New Drug , Incannex Board , Securities Litigation Reform Act , Executive Officer , Relations Contact , Nicotine Replacement Therapy , Nicotine Addiction , Food And Drug Administration , Chewing Gum , Development Program , Continued Development , The Company , Addiction , Cigarette Smoking , B1 Receptor , Smoking Cessation ,